Literature DB >> 29945931

Differential Tolerance to FTY720-Induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of Sphingosine-1-Phosphate Receptor Adaptation.

Laura J Sim-Selley1, Jenny L Wilkerson2, James J Burston2, Kurt F Hauser2, Virginia McLane2, Sandra P Welch2, Aron H Lichtman2, Dana E Selley2.   

Abstract

The immunomodulatory prodrug 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720), which acts as an agonist for sphingosine-1-phosphate (S1P) receptors (S1PR) when phosphorylated, is proposed as a novel pain therapeutic. In this study, we assessed FTY720-mediated antinociception in the radiant heat tail-flick test and in the chronic constriction injury (CCI) model of neuropathic pain in mice. FTY720 produced antinociception and antiallodynia, respectively, and these effects were dose-dependent and mimicked by the S1PR1-selective agonist CYM-5442. Repeated administration of FTY720 for 1 week produced tolerance to acute thermal antinociception, but not to antiallodynia in the CCI model. S1PR-stimulated [35S]GTPγS autoradiography revealed apparent desensitization of G protein activation by S1P or the S1PR1 agonist 5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole (SEW-2871) throughout the brain. Similar results were seen in spinal cord membranes, whereby the Emax value of S1PR-stimulated [35S]GTPγS binding was greatly reduced in repeated FTY720-treated mice. These results suggest that S1PR1 is a primary target of FTY720 in alleviating both acute thermal nociception and chronic neuropathic nociception. Furthermore, the finding that tolerance develops to antinociception in the tail-flick test but not in chronic neuropathic pain suggests a differential mechanism of FTY720 action between these models. The observation that repeated FTY720 administration led to desensitized S1PR1 signaling throughout the central nervous system suggests the possibility that S1PR1 activation drives the acute thermal antinociceptive effects, whereas S1PR1 desensitization mediates the following: 1) tolerance to thermal antinociceptive actions of FTY720 and 2) the persistent antiallodynic effects of FTY720 in neuropathic pain by producing functional antagonism of pronociceptive S1PR1 signaling.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29945931      PMCID: PMC6090176          DOI: 10.1124/jpet.118.248260

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

2.  The sphingosine 1-phosphate receptor, S1PR₁, plays a prominent but not exclusive role in enhancing the excitability of sensory neurons.

Authors:  Xian Xuan Chi; G D Nicol
Journal:  J Neurophysiol       Date:  2010-09-15       Impact factor: 2.714

3.  Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice.

Authors:  N W Pedigo; W L Dewey; L S Harris
Journal:  J Pharmacol Exp Ther       Date:  1975-06       Impact factor: 4.030

4.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

5.  Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist.

Authors:  Stuart M Cahalan; Pedro J Gonzalez-Cabrera; Nhan Nguyen; Miguel Guerrero; Elizabeth A George Cisar; Nora B Leaf; Steven J Brown; Edward Roberts; Hugh Rosen
Journal:  Mol Pharmacol       Date:  2012-11-30       Impact factor: 4.436

6.  The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.

Authors:  Kali Janes; Joshua W Little; Chao Li; Leesa Bryant; Collin Chen; Zhoumou Chen; Krzysztof Kamocki; Timothy Doyle; Ashley Snider; Emanuela Esposito; Salvatore Cuzzocrea; Erhard Bieberich; Lina Obeid; Irina Petrache; Grant Nicol; William L Neumann; Daniela Salvemini
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

7.  Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Authors:  S G Kinsey; J Z Long; S T O'Neal; R A Abdullah; J L Poklis; D L Boger; B F Cravatt; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2009-06-05       Impact factor: 4.030

8.  Distribution of sphingosine kinase activity and mRNA in rodent brain.

Authors:  Nicolas Blondeau; Yushuan Lai; Sarah Tyndall; Margherita Popolo; Kamil Topalkara; James K Pru; Ling Zhang; Hyunghwan Kim; James K Liao; Kan Ding; Christian Waeber
Journal:  J Neurochem       Date:  2007-07-10       Impact factor: 5.372

9.  Differential lumbar spinal cord responses among wild type, CD4 knockout, and CD40 knockout mice in spinal nerve L5 transection-induced neuropathic pain.

Authors:  Ling Cao; Holly Beaulac; Adriana Eurich
Journal:  Mol Pain       Date:  2012-12-18       Impact factor: 3.395

10.  Antinociceptive activity of the S1P-receptor agonist FTY720.

Authors:  Ovidiu Coste; Sandra Pierre; Claudiu Marian; Christian Brenneis; Carlo Angioni; Helmut Schmidt; Laura Popp; Gerd Geisslinger; Klaus Scholich
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

View more
  10 in total

1.  Activation of Sphingosine-1-Phosphate Receptor 1 in the Spinal Cord Produces Mechanohypersensitivity Through the Activation of Inflammasome and IL-1β Pathway.

Authors:  Timothy M Doyle; Zhoumou Chen; Mariaconcetta Durante; Daniela Salvemini
Journal:  J Pain       Date:  2019-02-23       Impact factor: 5.820

Review 2.  cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacology-tribute to Karl H. Jakobs.

Authors:  Klaus Aktories; Peter Gierschik; Dagmar Meyer Zu Heringdorf; Martina Schmidt; Günter Schultz; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-17       Impact factor: 3.000

3.  Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.

Authors:  Zhoumou Chen; Timothy M Doyle; Livio Luongo; Tally M Largent-Milnes; Luigino Antonio Giancotti; Grant Kolar; Silvia Squillace; Serena Boccella; John K Walker; Alexander Pendleton; Sarah Spiegel; William L Neumann; Todd W Vanderah; Daniela Salvemini
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-08       Impact factor: 11.205

4.  Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.

Authors:  Timothy M Doyle; Kali Janes; Zhoumou Chen; Peter M Grace; Emanuela Esposito; Salvatore Cuzzocrea; Tally M Largent-Milnes; William L Neumann; Linda R Watkins; Sarah Spiegel; Todd W Vanderah; Daniela Salvemini
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

5.  Sphingosine-1-phosphate receptor 1 agonist SEW2871 alters membrane properties of late-firing somatostatin expressing neurons in the central lateral amygdala.

Authors:  Briana E Mork; Sydney R Lamerand; Shudi Zhou; Bradley K Taylor; Patrick L Sheets
Journal:  Neuropharmacology       Date:  2021-11-16       Impact factor: 5.273

Review 6.  Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain.

Authors:  Marco Sisignano; Philip Gribbon; Gerd Geisslinger
Journal:  Drugs       Date:  2022-03-07       Impact factor: 9.546

7.  FTY720 Attenuates Neuropathic Pain after Spinal Cord Injury by Decreasing Systemic and Local Inflammation in a Rat Spinal Cord Compression Model.

Authors:  Kazuyoshi Yamazaki; Masahito Kawabori; Toshitaka Seki; Soichiro Takamiya; Takahiro Tateno; Kotaro Konno; Masahiko Watanabe; Kiyohiro Houkin
Journal:  J Neurotrauma       Date:  2020-05-18       Impact factor: 5.269

8.  Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain.

Authors:  Ricardo Vallejo; Courtney A Kelley; Ashim Gupta; William J Smith; Alejandro Vallejo; David L Cedeño
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

Review 9.  S1P/S1P Receptor Signaling in Neuromuscolar Disorders.

Authors:  Elisabetta Meacci; Mercedes Garcia-Gil
Journal:  Int J Mol Sci       Date:  2019-12-17       Impact factor: 5.923

10.  Exosomes Derived from Nerve Stem Cells Loaded with FTY720 Promote the Recovery after Spinal Cord Injury in Rats by PTEN/AKT Signal Pathway.

Authors:  Jianbin Chen; Can Zhang; Shouye Li; Zheming Li; Xiaojing Lai; Qingqing Xia
Journal:  J Immunol Res       Date:  2021-07-14       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.